Pricing Log in Create free account

Aclaris Therapeutics, Inc. (ACRS) vs Climb Bio, Inc. (CLYM)

Aclaris Therapeutics, Inc. and Climb Bio, Inc. are both Biotechnology companies. Aclaris Therapeutics, Inc. and Climb Bio, Inc. are of similar size ($560.0M and $550.5M). Climb Bio, Inc. has the higher net margin (0.00% vs −921.5%) and the higher return on invested capital (−71.7% vs −163.4%). Across the 12 metrics below, Climb Bio, Inc. leads on 10 and Aclaris Therapeutics, Inc. on 2.

Valuation

Metric ACRS CLYM Biotechnology median
P/E n/m n/m 10.64
P/S 64.95 n/m 9.59
P/B 4.29 3.10 2.15
Price to free cash flow n/m n/m 26.07
EV/EBITDA n/m n/m 0.65
EV/Sales 55.12 n/m 9.45
Earnings yield (15.51%) (8.51%) (34.69%)
Free cash flow yield (11.65%) (7.16%) (24.02%)

Profitability

Metric ACRS CLYM Biotechnology median
Gross margin 12.90% — 65.59%
Operating margin (1,050.16%) 0.00% 0.00%
Net margin (921.50%) 0.00% 0.00%
Free cash flow margin (756.50%) 0.00% 0.00%
Return on equity (59.10%) (27.10%) (51.96%)
Return on assets (41.07%) (26.27%) (46.06%)
Return on invested capital (163.35%) (71.73%) 0.00%

Growth

Metric ACRS CLYM Biotechnology median
Revenue growth (TTM) (51.04%) — 4.59%
EPS growth (last fiscal year) 69.01% 42.48% 29.88%
Revenue growth, 5-year CAGR 3.84% — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACRS CLYM Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.46 31.45 4.86
Net debt to EBITDA 1.20 1.44 1.01

Dividend

Metric ACRS CLYM Biotechnology median
Dividend yield — — 0.38%
Payout ratio — — —

Size

Metric ACRS CLYM Biotechnology median
Market cap 550.53m 560.00m 174.29m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack